A phase 3 trial evaluates the efficacy and safety of maintenance therapy with rituximab and lenalidomide vs rituximab alone in older patients with relapsed/refractory follicular lymphoma.

AbbVie (NYSE: ABBV) announced today that Health Canada has issued a Notice of Compliance for EPKINLY® (epcoritamab) with a new follicular lymphoma (FL) indication. EPKINLY®, in combination with ...

U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for the treatment of refractory rheumatoid arthritis Artiva to host ...

AbbVie (ABBV) said Thursday that Health Canada issued a Notice of Compliance for EPKINLY, or epcoritamab, for a new indication to treat adults with follicular lymphoma, a subtype ...

Nephrotic syndrome is caused when the filtering system in the kidneys is damaged, allowing large amounts of protein to leak into the urine. It is usually treated with steroids, but in some cases, ...

Rituximab is a chimeric human/mouse monoclonal antibody that is approved for the treatment of relapsed and refractory non-Hodgkin's lymphoma (NHL) and in combination with CHOP (cyclophosphamide, ...

Please provide your email address to receive an email when new articles are posted on . Learning from 2 decades of off-label rituximab use in systemic lupus erythematosus may point the way toward ...

Although rituximab may improve central nervous system outcomes, evidence supporting its use in Sjögren disease is limited. Rituximab may improve neurologic outcomes in adults with severe or ...

Nephrotic syndrome is caused when the filtering system in the kidneys is damaged, allowing large amounts of protein to leak into the urine.

Rituximab effectively reduced skin sclerosis and appeared to have a beneficial effect on interstitial lung disease (ILD) for patients with systemic sclerosis (SSc) in a randomized, clinical trial. At ...

Although the anti-CD20 B-cell depleting biological agent rituximab has been shown in small series and single-arm studies to effectively treat frequently relapsing nephrotic syndrome (FRNS) and steroid ...

In a new study, rituximab therapy was found to be an effective treatment option for lupus nephritis (LN) management. After six months of use, people with lupus nephritis taking the therapy showed ...